Gynäkologische Endokrinologie

, Volume 8, Issue 1, pp 35–40 | Cite as

Hormonersatztherapie nach Mamma- und Ovarialkarzinom

  • M. Thill
  • D. Fischer
  • K. Röder
  • D.W. Lüdders
  • K. Diedrich
  • C. Dittmer
Leitthema
  • 66 Downloads

Zusammenfassung

Frauen, die an einem Mammakarzinom behandelt wurden, leiden unter dem konsekutiven Östrogenmangel einer Chemo- oder antiendokrinen Therapie. Diese Frauen würden erheblich von einer Hormonsubstitution profitieren. Die Datenlage dazu ist allerdings inkonsistent. Zahlreiche Beobachtungsstudien konnten kein erhöhtes Rezidivrisiko unter Hormonersatztherapie (HRT) zeigen, allerdings waren viele dieser Arbeiten sehr heterogen, retrospektiv und hatten eine zu geringe Fallzahl. Die wenigen prospektiven Studien suggerieren eine Erhöhung des Rezidivrisikos unter HRT. Auch das Ovarialkarzinom ist ein hormonabhängiges Malignom, weshalb eine HRT in der Peri- und Postmenopause einen Einfluss auf das Erkrankungsrisiko haben kann, insbesondere nach behandelter Erkrankung. Die Datenlage zur Wirkung einer HRT auf das Ovarialkarzinom ist dünn. Epidemiologische Studien zeigen, dass eine langfristige HRT das Ovarialkarzinomrisiko möglicherweise erhöht. Noch spärlicher sind die Daten zum Einsatz einer HRT nach Ovarialkarzinombehandlung. Zuverlässige Empfehlungen lassen sich daraus nicht ableiten. Ziel dieser Arbeit ist es, aus der aktuellen Datenlage die Frage nach der Durchführbarkeit einer HRT zu eruieren und möglicherweise neue Empfehlungen daraus zu erhalten.

Schlüsselwörter

Mammakarzinom Ovarialkarzinom Hormonersatztherapie Rezidivrisiko Menopause 

Hormone replacement therapy after breast and ovarian cancer

Abstract

Breast cancer patients undergoing chemotherapy or anti-endocrine treatment suffer from a subsequent lack of estrogen. While these women would benefit substantially by estrogen replacement, the pertinent data are sparse and inconsistent. Observational studies have not shown an increased risk of recurrence under hormone replacement therapy (HRT); however, the studies are heterogeneous, retrospective and mostly underpowered. The few randomized prospective studies suggest an increased recurrence rate with HRT regimens. Since ovarian cancer is a hormone-related malignancy as well, HRT in perimenopausal and postmenopausal women may have an impact on ovarian cancer risk, especially after primary treatment, but data are scanty. Epidemiological studies have shown that long-term HRT might even increase the risk of ovarian cancer The data on HRT after ovarian cancer treatment are even scantier ; thus, there are no reliable recommendations. This paper reviews the current literature concerning the feasibility of HRT in order to develop new recommendations.

Keywords

Breast cancer Ovarian cancer Hormone replacement therapy Recurrence risk Menopause 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Allemand H, Seradour B, Weill A et al (2008) Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend. Bull Cancer (Paris) 95:11–15Google Scholar
  2. 2.
    Antoine C, Liebens F, Carly B et al (2007) Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review. Climacteric 10(1):23–26CrossRefPubMedGoogle Scholar
  3. 3.
    Batur P, Blixen CE, Moore HC et al (2006) Menopausal hormone therapy (HT) in patients with breast cancer. Maturitas 53(2):123–132CrossRefPubMedGoogle Scholar
  4. 4.
    Biglia N, Cozzarella M, Cacciari F et al (2003) Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 45(1):29–38CrossRefPubMedGoogle Scholar
  5. 5.
    Biglia N, Mariani L, Marenco D et al (2006) Homone replacement therapy after gynaecological cancer. Gynakol Geburtshilfliche Rundsch 46(4):191–196CrossRefPubMedGoogle Scholar
  6. 6.
    Canfell K, Banks E, Moa AM, Beral V (2008) Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188:641–644PubMedGoogle Scholar
  7. 7.
    Col NF, Hirota LK, Orr RK et al (2001) Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 19:2357–2363PubMedGoogle Scholar
  8. 8.
    Col NF, Kim JA, Chlebowski RT (2005) Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 7(4):R535–R540CrossRefPubMedGoogle Scholar
  9. 9.
    Coughlin SS, Giustozzi A, Smith SJ, Lee NC (2000) A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 53:367–375CrossRefPubMedGoogle Scholar
  10. 10.
    Eeles RA, Tan S, Witshaw E et al (1991) Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302:259–262CrossRefPubMedGoogle Scholar
  11. 11.
    Emons G (2002) Hormonsubstitution nach Mammakarzinom. Gynäkologe 35:1114–1116Google Scholar
  12. 12.
    Garg PP, Kerlikowske K, Subak L, Grady D (1998) Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92:472–479CrossRefPubMedGoogle Scholar
  13. 13.
    Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. und das Robert Koch Institut (2006) Krebs in Deutschland – Häufigkeiten und Trends. RoBo Print, Riegelsberg SaarbrückenGoogle Scholar
  14. 14.
    Gorins A, Espié M, Bedairia N et al (2006) Hormonal replacement therapy in menopause after breast cancer: first french study. Contracept Fertil Sex 26(10):696–699Google Scholar
  15. 15.
    Gorins A, Espie M, Bedairia N et al (2003) Hormone replacement therapy in breast cancer patients: a study of 230 patients, with a case-control study. Gynecol Obstet Fertil 31:614–619CrossRefPubMedGoogle Scholar
  16. 16.
    Guidozzi F, Daponte A (1999) Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer 86:1013–1018CrossRefPubMedGoogle Scholar
  17. 17.
    Holli K, Isola J, Cuzick J (1998) Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16(9):3115–3120PubMedGoogle Scholar
  18. 18.
    Holmberg L, Anderson H (2004) HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet 363:453–455CrossRefPubMedGoogle Scholar
  19. 19.
    Holmberg L, Iversen OE, Rudenstam CM et al (2008) HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100(7):475–482. Erratum in: J Natl Cancer Inst 100(9):685Google Scholar
  20. 20.
    Katalinic A, Rawal R (2008) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107:427–430CrossRefPubMedGoogle Scholar
  21. 21.
    Katalinic A, Lemmer A, Zawinell A et al (2009) Trends in hormone therapy and breast cancer incidence – results from the German Network of Cancer Registries. Pathobiology 76(2):90–97CrossRefPubMedGoogle Scholar
  22. 22.
    Marsden J, A’Hern R (2003) The Million Women Study and breast cancer. J Br Menopause Soc 9(3):95–97CrossRefPubMedGoogle Scholar
  23. 23.
    Mascarenhas C, Lambe M, Bellocco R et al (2006) Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 119(12):2907–2915CrossRefPubMedGoogle Scholar
  24. 24.
    Mørch LS, Løkkegaard E, Andreasen AH et al (2009) Hormone therapy and ovarian cancer. JAMA 302(3):298–305CrossRefPubMedGoogle Scholar
  25. 25.
    North American Menopause Society (2004) Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 11:11–33CrossRefGoogle Scholar
  26. 26.
    Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674CrossRefPubMedGoogle Scholar
  27. 27.
    Rodriguez C, Patel AV, Calle EE et al (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285:1460–1465CrossRefPubMedGoogle Scholar
  28. 28.
    Rossing MA, Cushing-Haugen KL, Wicklund KG et al (2007) Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 16(12):2548–2556CrossRefPubMedGoogle Scholar
  29. 29.
    Ursic-Vrscaj M, Bebar S, Zakelj MP (2001) Hormone replacement therapy after invasive ovarian serous cystoadenocarcinoma treatment: the effect on survival. Menopause 8:70–75CrossRefPubMedGoogle Scholar
  30. 30.
    Vankrunkelsven P, Kellen E, Lousbergh D et al (2009) Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 118(2):425–432CrossRefPubMedGoogle Scholar
  31. 31.
    Vassilopoulou-Sellin R, Klein MJ (1996) Estrogen replacement therapy after treatment for localized breast carcinoma. Patient responses and opinions. Cancer 78(5):1043–1048. Erratum in: Cancer 79(4):867Google Scholar
  32. 32.
    Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN et al (2002) Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer 95:1817–1826CrossRefPubMedGoogle Scholar
  33. 33.
    Von Schoultz E, Rutqvist LE, on behalf of the Stockholm Breast Cancer Study Group (2005) Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 97:533–535CrossRefGoogle Scholar
  34. 34.
    Wernli KJ, Newcomb PA, Hampton JM et al (2008) Hormone therapy and ovarian cancer: incidence and survival. Cancer Causes Control 19(6):605–613CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2009

Authors and Affiliations

  • M. Thill
    • 1
  • D. Fischer
    • 1
  • K. Röder
    • 1
  • D.W. Lüdders
    • 1
  • K. Diedrich
    • 1
  • C. Dittmer
    • 1
  1. 1.Klinik für Frauenheilkunde und GeburtshilfeUniversitätsklinikum Schleswig-Holstein, Campus LübeckLübeckDeutschland

Personalised recommendations